Blas Chaves-Urbano @blaschaves_

PhD student at @CNIOStopCancer | La Caixa INPhINIT Retaining Fellow @BecariosFLC linkedin.com/in/blas-chaves… Madrid, Spain Joined September 2019

Tweets

160
Followers

241
Following

652
Likes

361

Barbara Hernando @BHFHeptathlon

8 months ago

📢 New preprint out! We are thrilled to introduce our framework to track #ongoingCIN by leveraging single-cell genomics and CIN signatures: biorxiv.org/content/10.110…

1 8 9 769 0

View Details

Blas Chaves-Urbano @blaschaves_

8 months ago

Very excited to share my PhD journey (and those of my colleagues) supported by @BecariosFLC ! 🚀🚀 Check out the videos to learn more about our research 👇

Becas Fundación "la Caixa" @BecariosFLC

8 months ago

1/ 🌟 Curious about today’s most cutting-edge research? Today, 1⃣6⃣ INPhINIT doctoral #laCaixaFoundFellows are taking on a challenge: explaining their PhD projects in a way that’s engaging and easy to understand. Listen to their “Shooting your PhD”: 👇 tinyurl.com/y6v5dad4

1 1 1 342 0

0 0 0 158 0

View Details

Hereditary Endocrine Cancer Group @CNIOStopCancer @Endocrine_CNIO

10 months ago

Another year, another European Researchers Night #NIGHTMADRID at @CNIOStopCancer. @Endocrine_CNIO and friends ready to rock this exciting event!!

0 5 15 978 1

View Details

EL PAÍS @el_pais

a year ago

Descubierto un marcador que indica qué pacientes no responderán a la quimioterapia. La genética de sus tumores puede desvelar qué fármaco no funcionará, lo que ayudaría a los oncólogos a aplicar otro tipo de quimio que sí podría tener efecto social.elpais.com/7rew21

0 130 318 26K 19

View Details

CNIO Stop Cancer @CNIOStopCancer

a year ago

#CNIOStopCancer develop test that predicts which patients will not respond to cancer chemotherapy. They have identified biomarkers which, in clinical practice, would allow for more effective treatments and the avoidance of side effects. bit.ly/465QqnR

1 5 12 763 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

🚨Chemo treatment upgrade!🚨 Check out our approach to modernise chemotherapy treatment published today in @NatureGenet. From @CNIOStopCancer @TailorBio @CR_UK nature.com/articles/s4158… More details 👇

2 23 45 4K 11

View Details

Blas Chaves-Urbano @blaschaves_

a year ago

A pleasure to be at the fantastic #EACR2025 and present my research project! Looking forward for cool scientific discussions with amazing cancer researchers and friends @EACRnews @CNIOStopCancer @BecariosFLC @gjmacintyre

2 7 51 2K 1

View Details

Barbara Hernando @BHFHeptathlon

a year ago

💥New preprint from the @gjmacintyre lab! Thrilled to share this major team effort, with @Sanroman_Fern as co-first author, now live on bioRxiv! Check out our threat to learn more about our work👇

Geoff Macintyre @gjmacintyre

a year ago

If tumour genome evolution is deterministic, can we forecast genomic changes? Yes we can! At least for oncogene amps and tumour suppressor dels. @BHFHeptathlon @Sanroman_Fern present our method for forecasting driver gene copy number change. Preprint: bit.ly/4kxF14y ⬇️1/

1 16 37 5K 12

0 4 9 1K 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

@MaxGalder @blaschaves_ @m_escobarrey @patricgsant @alicecadiz_ @LuisPaz_Ares @JuanMaCoya @dagsbio

0 1 4 288 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

…and to the patients and funders @CNIOStopCancer @SaludISCIII @CienciaGob @BecariosFLC @H12Octubre

1 1 4 273 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

TL;DR Forecasting oncogene amps & tumour suppressor dels is feasible! This can refine risk stratification and anticipate treatment resistance, paving the way for earlier, smarter and more personalised cancer care. There is much more in the preprint so check it out! 13/

1 1 2 136 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

MET amps cause EGFRi resistance in ~25% of NSCLCs. Forecasting MET amp in 33 EGFR-mutant NSCLC tumours treated with osimertinib showed high-risk patients had shorter PFS & OS. This can be used to flag candidates for upfront EGFR+MET inhibition (eg MARIPOSA trial) 12/

1 1 2 192 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

Currently, LGGs are classified into 4 WHO risk groups. CDK4/PDGFRA amps and CDKN2A dels are linked with poor prognosis but under utilised. Forecasting these facilitates a risk upgrade of 9% of IDHmut-non-codel cases while maintaining median survival times across WHO groups 11/

1 1 2 150 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

Encouraging right? We then applied our approach to two clinical scenarios where forecasting specific genetic changes might unlock new clinical opportunities: risk stratification of low-grade glioma (LGG) and anticipation of osimertinib resistance in lung cancer 10/

1 1 2 142 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

Next we tested longitudinal pairs, forecasting at the early time point (before driver amp) and testing at the latter. In prostate, we predicted AR amp (linked to ADT resistance) in pretreatment samples. In NSCLC, we predicted HIST1H3B amp (exclusive to metastases) in primaries 9/

1 1 2 162 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

First, we tested performance on two independent cohorts: PCAWG: 2,114 primaries; HMF: 4,784 metastases. 147 of the 241 models showed AUC > 0.7 across both datasets 8/

1 1 2 142 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

We trained this model for 241 drivers using 7,880 TCGA samples across 33 tumour types. But do these models work? 7/

1 1 2 118 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

Challenge 3: forecasting in a clinical setting. Solution: binarise predictions and only use standard genomic test data as input. We designed guidelines to apply and (if needed) train the model + optimize thresholds for binary risk classification (high vs low) 6/

1 1 1 144 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

Challenge 2: growth rates of mutant vs non-mutant cells (and thus selection) cannot be easily determined in a clinical context. Solution: approximate selection coeffs using driver amp/del frequency at a population-level (supported by recent work showing s≈fβ) 5/

1 1 3 141 0

View Details

Geoff Macintyre @gjmacintyre

a year ago

Challenge 1: amp/del rates cannot be readily measured from an input genome. Solution: approximate using a steady-state probability of locus-specific copy number change over tumour lifetime. We adapted our previous CIN signatures (CX bit.ly/42SVA3i) for this 4/